港股异动 | 歌礼制药-B涨11% 向美国FDA递交口服抗病毒药物ASC10的猴痘适应症新药临床试验申请
格隆汇10月27日丨歌礼制药-B(1672.HK)涨11.16%,报2.69港元,总市值29亿港元。歌礼制药26日在港交所公吿,已向美国食品药品监督管理局(FDA)递交针对猴痘病毒聚合酶的口服抑制剂候选药物ASC10的新药临床试验(IND)申请。临床前研究显示,ASC10对猴痘病毒和新型冠状病毒具有强效抗病毒活性。ASC10拥有两项适应症:猴痘病毒以及新型冠状病毒感染。2022年8月,美国食品药品监督管理局(FDA)已批准ASC10新冠感染适应症新药临床试验申请(IND),目前该项在新冠患者中开展的Ib期临床试验正在美国有序进行。在美国递交ASC10猴痘适应症新药临床试验申请将进一步拓宽歌礼病毒性疾病管线布局。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.